Melissa Dolan

[The Buffalo News @TheBuffaloNews]

Rod Watson: UB grad's success shows value of strong support network https://t.co/Jh95kGUmKg

[Melissa Dolan @mdolan1118]

So incredibly proud! Can’t wait to frame it and print it on a cocoa mug ❤️

[Rasheen Powell, Ph.D. @PowellRasheen]

What a morning. A beautiful Bills win yesterday...and my thesis work has been published in Nature Communications! This couldn't have been possible without the help of @Bleed_Oil,@GarrettDSheehan ,@ultrav1ol3t13 , and @KerriPryce https://t.co/MidMV4A0nb

[Mark Yarchoan @MarkYarchoan]

Delighted to share our experience with neoadjuvant TKI+PD1 therapy in HCC beyond traditional resection criteria in Nature Cancer. https://t.co/7QpHK1c7WW. Cliff notes:

[Anna Obenauf @obenaufa]

We are so excited to finally share our new study reporting the evolution of cross-resistance between targeted therapy and immunotherapy, published today @NatureCancer. Highlights in the 🧵👇 Free access here https://t.co/TasdMFh7gR 1/25

[Roswell Park PhD Students @RoswellParkPhD]

Today’s an exciting day for the Pharmacology and Therapeutics Department as @tshi42 from @EbosLab is defending his thesis! Congrats Dr. Shi and best of luck as you finish your MD!!

[Roswell Park PhD Students @RoswellParkPhD]

Tune in today at 3pm to watch our very own @tshi42, MD/PhD students in Experimental Therapeutics, from the @EbosLab as he competes in The University at Buffalo's 3 Minute Thesis Competition!

Join at 3pm by using the link found here: https://t.co/aMf5OaKP1i

Good luck, Tom!

[Cancer Cell @Cancer_Cell]

Online Now: Immunomodulation by targeted anticancer agents https://t.co/IEDSaNOxJY

[Cancer Research Institute @CancerResearch]

According to a new analysis led by our Clinical Accelerator team and @IQVIA_global, VEGF/VEGFR targeted therapy has emerged as the top combination treatment with PD-1/L1 checkpoint inhibitors in clinical trials in 2020. 📈 #SITC2020 https://t.co/pKbsER3bIc

[John Ebos @EbosLab]

Check out Yuhao (Tom) Shi @tshi42 from @EbosLab presenting his poster today #SITC2020. Listen to the audio summary and ask questions! @RoswellPark @GeneticsRoswell

[KidneyCAN @kidneycan]

Heading to DC for #kidneycancer Advocacy Days. Saw this from @DrChoueiri @DanaFarber @EbosLab. This is what we are fighting for @CDMRP!
https://t.co/AqwCphg7Z3

[Toni Choueiri, MD @DrChoueiri]

THANK YOU @CDMRP for highlighting #KidneyCancer research @DanaFarber with @XShirleyLiu & @RoswellPark with @EbosLab looking at 2 approaches aimed at harnessing predictive markers of response to antiangiogenics in metastatic RCC https://t.co/qF98GeYEZm

[PeerView @PeerView]

How do you optimally select and sequence newer regimens for patients throughout the advanced #RCC continuum? Hear @DrChoueiri discuss during #IKCS2019 on 11/16 at 10:33 AM. https://t.co/W1zFqPrpsf @KidneyCancer

[Nature Portfolio @NaturePortfolio]

News & Views: Chemotherapy-treated cancer cells that enter a non-dividing state called senescence can still boost cancer growth. A study showing that these cells eat neighbouring cells reveals a mechanism that enables senescent cells to persist. https://t.co/EgTVRmCMJJ

[Nature Reviews Cancer @NatureRevCancer]

Most studies looking at therapy resistance have focused on tumour-intrinsic changes, yet it's now clear that host responses to different cancer therapies can contribute to tumour regrowth, spread & resistance. Find out more in our Review from Yuval Shaked https://t.co/tWTajkf7M2

[Wendy Woodward MDPhD @IBCradiation]

Dr. Ashani Weeraratna - Newest discoveries in metastasis - microenvironment is key! "Pseudo senescent" cells are MORE invasive! Tumor cells can crawl along the outside of vessels without invading them, and age decreases collagen, increases invasion in tissue and vessels! #ASTRO19

[Dana-Farber News @DanaFarberNews]

Newly published research in @JAMAOnc validates past research published by @DrChoueiri and @VanAllenLab — PBRM1 gene alterations may be a marker of response to second line nivolumab in advanced #kidneycancer: https://t.co/7v2yhIi9ax #kcsm

[Toni Choueiri, MD @DrChoueiri]

Very important unmet need —-what to do after IO? I personally like new targets ! Can you rechallenge with IO? All open questions @KCA_Journal @PrimoLaraMD #RCC #kcsm

[UroToday.com @urotoday]

"What is driving the response and resistance to these existing adjuvant therapies in advanced disease? @BraunMDPhD @DanaFarber Innovative research for advanced #KidneyCancer. Understanding and improving immunotherapies. @CaPsurvivorship @NUFeinbergMed https://t.co/FLdLmrQSUQ

[Katherine Aird @airdlab]

I'm so excited to share @BioYupi's work on a new role for p16 loss in regulating nucleotide synthesis! Keep reading for a Tweetorial! 1/n

https://t.co/pXkBYlggfg

[nature @Nature]

New insights into how chemotherapy may cause cancer cells to sleep but not die. https://t.co/kmYmNl9Vn7